Hydrocortisone – topicalClassification: B
Drug products: Cortimyk, Daktacort®, Fenuril®-Hydrokortison, Ficortril®, Fucidin®-Hydrocortison, Fucidin-Hydrocortison, Fusidinsyra/Hydrokortison 2care4, Hydrokortison Apofri, Hydrokortison Evolan, Hydrokortison PharmSwed, Hydrokortison-svavel i Essex kräm APL, Locoid, Locoid Crelo, Locoid Lipid, Locoid®, Mildison Lipid, Softacort, Terracortril med polymyxin B, Terracortril med Polymyxin B, Terra-Cortril med polymyxin B, Terracortril®, Terracortril® med Polymyxin B, Uniderm®, Xerclear, Zoviduo
ATC code: D01AC20, D06BB53, D07AA02, D07AB02, D07CA01, D07XA01, S01BA02, S03CA04
Published controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of topical hydrocortisone are lacking.
Pharmacokinetics and dosing
No studies with a clinical relevant sex analysis regarding the pharmacokinetics or dosing of topical hydrocortisone have been found.
No studies with a clinical relevant sex analysis regarding the effects of topical hydrocortisone have been found.
No studies with a clinical relevant sex analysis regarding the adverse effects of topical hydrocortisone have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men .
Date of litterature search: 2022-06-29
Reviewed by: Diana Rydberg
Approved by: Karin Schenck-Gustafsson